
|Videos|December 4, 2021
Lutetium 177 PSMA enhances QOL in patients with mCRPC
Author(s)Urology Times staff
"The results of this trial impacted practice globally,” says Michael J. Morris, MD.
Advertisement
In this video, Michael J. Morris, MD, discusses the background, findings, and takeaways of the VISION trial, which was presented recently at the 2021 Society of Urologic Oncology Annual Meeting. Morris is the section head of prostate cancer in the GU oncology service at the Memorial Sloan Kettering Cancer Center in New York, New York.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
3
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
4
Michael Cookson, MD, discusses new strategies for treatment intensification in prostate cancer
5


















